GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers (877) 841-3961
Non-US callers (201) 689-8589
Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen’s website at: http://investor.inogen.com/. This webcast will also be archived on the website for 6 months.
A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through March 5, 2024. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13743411.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.
For more information, please visit www.inogen.com.
Contacts
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC)…
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation…
Toronto, Ontario--(Newsfile Corp. - November 4, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or…
HSINCHU, Nov. 3, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier…
Health Union's enhanced research suite expands its core patient and caregiver offerings to fully incorporate…
SANTA CLARA, Calif., Nov. 3, 2025 /PRNewswire/ -- Introduction AIxMed, a recognized innovator in AI…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
